BridgeBio Non Currrent Assets Other from 2010 to 2025
| BBIO Stock | USD 33.75 1.56 4.85% |
Non Currrent Assets Other | First Reported 2018-12-31 | Previous Quarter 20.3 M | Current Value 18.2 M | Quarterly Volatility 13.2 M |
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers, such as Interest Income of 18.1 M, Depreciation And Amortization of 6.4 M or Interest Expense of 104.3 M, as well as many indicators such as Price To Sales Ratio of 21.86, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 7.38. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
BridgeBio | Non Currrent Assets Other |
Latest BridgeBio Pharma's Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of BridgeBio Pharma over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. BridgeBio Pharma's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Pharma's overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
BridgeBio Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 8,177,400 | |
| Coefficient Of Variation | 140.92 | |
| Mean Deviation | 10,219,125 | |
| Median | 473,000 | |
| Standard Deviation | 11,523,989 | |
| Sample Variance | 132.8T | |
| Range | 37.9M | |
| R-Value | 0.72 | |
| Mean Square Error | 67.6T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 1,754,050 | |
| Total Sum of Squares | 1992T |
BridgeBio Non Currrent Assets Other History
About BridgeBio Pharma Financial Statements
BridgeBio Pharma investors utilize fundamental indicators, such as Non Currrent Assets Other, to predict how BridgeBio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 18.2 M | 15.4 M |
Check out the analysis of BridgeBio Pharma Correlation against competitors. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth 2.371 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.